Summary: There is no known clinically significant pharmacokinetic interaction between Wegovy (semaglutide) and ADHD stimulants, but combining them requires careful medical supervision due to overlapping effects on appetite and cardiovascular function
Sometimes insurance coverage changes
While the gastrointestinal effects (nausea, diarrhea, vomiting) are similar to other GLP-1 medications like Wegovy and Mounjaro, retatrutide has one unique finding: dysesthesia (abnormal touch sensations) in 20.9% of patients at the 12mg dose in TRIUMPH-4, and 12.5% at 12mg in the larger TRIUMPH-1 trial
These compounded drugs, which are not approved by the FDA, have some safety concerns
GLP-1 injections typically cause less discomfort than many other injectable medications due to their very fine needles (2932 gauge) and short length (48 mm)
Most research supports doses between 200-400 mcg daily for general metabolic support, while specialized applications may utilize higher doses up to 1000 mcg